- Conditions
- Anemia
- Interventions
- ACE-536, Placebo
- Biological · Other
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 9,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma Multiforme
- Interventions
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
- Drug · Radiation · Device
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Healthy Volunteers
- Interventions
- BIIB104 Reference Formulation, BIIB104 Test Formulation
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
- Interventions
- BLU-701, osimertinib, carboplatin, pemetrexed
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
- Conditions
- Renal Impairment
- Interventions
- ESK-001
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 4
- States / cities
- Miami, Florida • Miami Lakes, Florida • Orlando, Florida
- Conditions
- Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ketoconazole, Healthy Adult Volunteers
- Interventions
- Isavuconazole, Ketoconazole
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Healthy
- Interventions
- palbociclib capsule: phase 1 and 2 studies, Palbociclib capsule: phase 3 studies, Palbociclib capsule: ICH
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Adult Solid Neoplasm
- Interventions
- Belinostat, Isotretinoin, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 5
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 2 more
- Conditions
- HER2-Positive Solid Tumor
- Interventions
- YH32367
- Drug
- Lead sponsor
- Yuhan Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- HIV Infections
- Interventions
- VRC07-523LS
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Seattle, Washington
- Conditions
- Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Hemispheric Glioma, H3G34 Mutant
- Interventions
- ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT)
- Drug · Radiation
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2035
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy
- Interventions
- Palbociclib alone, Palbociclib + Rabeprazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Solid Tumor, Advanced Solid Tumor
- Interventions
- PYX-201
- Drug
- Lead sponsor
- Pyxis Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 13 more
- Conditions
- Lung Cancer
- Interventions
- Niraparib, Osimertinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Parkinson's Disease
- Interventions
- MSK-DA01, MSK-DA01 Cell Delivery Device
- Biological · Device
- Lead sponsor
- BlueRock Therapeutics
- Industry
- Eligibility
- 50 Years to 78 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Orange, California • New York, New York
- Conditions
- Gout, Hyperuricemia
- Interventions
- Uricase-PEG 20
- Biological
- Lead sponsor
- EnzymeRx
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Miami, Florida • Duncansville, Pennsylvania
- Conditions
- Medical Oncology
- Interventions
- BAY1217389, Paclitaxel
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Food Effect of Tivozanib in Health Subjects
- Interventions
- tivozanib
- Drug
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Solid Tumor
- Interventions
- STP938
- Drug
- Lead sponsor
- Step Pharma, SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- St. Petersburg, Florida • Dallas, Texas • San Antonio, Texas
- Conditions
- Healthy, Volunteer
- Interventions
- Mirdametinib, Mirdametinib and Carbamazepine
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy Female Volunteers
- Interventions
- PF-06700841, Ethinyl estradiol (EE) and levonorgestrel (LN)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Coral Gables, Florida • Miami, Florida
- Conditions
- Healthy
- Interventions
- CT-P17
- Biological
- Lead sponsor
- Celltrion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Thyroid Cancer
- Interventions
- KTN3379, vemurafenib
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- rAAV1.CMV.huFollistin344
- Biological
- Lead sponsor
- Jerry R. Mendell
- Other
- Eligibility
- 7 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio